Sera Prognostics, Inc. (SERA)
2.03
-0.04
(-1.93%)
USD |
NASDAQ |
Oct 15, 16:00
2.07
+0.04
(+1.97%)
After-Hours: 20:00
Sera Prognostics Research and Development Expense (Quarterly) : 3.331M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.331M |
| March 31, 2026 | 2.866M |
| December 31, 2025 | 3.001M |
| September 30, 2025 | 3.07M |
| June 30, 2025 | 3.129M |
| March 31, 2025 | 3.147M |
| December 31, 2024 | 2.947M |
| September 30, 2024 | 3.301M |
| June 30, 2024 | 4.058M |
| March 31, 2024 | 3.47M |
| December 31, 2023 | 3.683M |
| September 30, 2023 | 3.191M |
| June 30, 2023 | 3.357M |
| Date | Value |
|---|---|
| March 31, 2023 | 3.738M |
| December 31, 2022 | 3.485M |
| September 30, 2022 | 4.176M |
| June 30, 2022 | 3.261M |
| March 31, 2022 | 3.322M |
| December 31, 2021 | 3.075M |
| September 30, 2021 | 2.724M |
| June 30, 2021 | 2.824M |
| March 31, 2021 | 2.396M |
| December 31, 2020 | 2.092M |
| September 30, 2020 | 1.888M |
| June 30, 2020 | 1.752M |
| March 31, 2020 | 2.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Myriad Genetics, Inc. | 25.00M |
| BioRestorative Therapies, Inc. | 1.926M |
| CareDx, Inc. | 22.38M |
| Natera, Inc. | 228.07M |
| Exagen, Inc. | 1.426M |